NCT06799676View on ClinicalTrials.gov

A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

October 31, 2027

Conditions
Newly Diagnosed Multiple Myeloma
Interventions
DRUG

a combination treatment of Linperlisib and the VRD regimen

Subjects will be administered Linperlisib orally at doses of 40 mg, 60 mg, or 80 mg once daily for 4 consecutive weeks, combined with the VRD regimen at standard doses. Subsequently, during the expansion phase, at least four cycles of Linperlisib at the recommended Phase II dose (RP2D) will be combined with the VRD regimen for induction therapy.

Trial Locations (3)

430071

Zhongnan Hospital of Wuhan University, Wuhan

437100

Xianning Central Hospital, Xianning

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Fuling Zhou

OTHER

NCT06799676 - A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | Biotech Hunter | Biotech Hunter